Literature DB >> 8083367

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

P de Knijff1, A M van den Maagdenberg, D I Boomsma, A F Stalenhoef, A H Smelt, J J Kastelein, A D Marais, R R Frants, L M Havekes.   

Abstract

Genetic and biochemical studies were carried out in 96 relatives of six independently ascertained probands with familial dysbetalipoproteinemia (FD) carrying the APOE*2 (Lys146-->Gln) allele. Compared to noncarriers, the 40 heterozygous APOE*2 (Lys146-->Gln) allele carriers exhibited markedly increased mean levels of cholesterol and triglyceride in the very low density lipoproteins (VLDL) (1.89 +/- 0.37 vs 0.30 +/- 0.27 and 1.86 +/- 0.37 vs 0.68 +/- 0.27 mmol/liter, respectively) and plasma apolipoprotein (apo) E levels (28.1 +/- 1.6 vs 4.6 +/- 1.1 mg/dl), which is characteristic for FD. By means of a pedigree-based maximum likelihood method we calculated that carrier-status accounted for 57% and 71%, respectively, of the total variance of the ratio (VLDL + IDL)-cholesterol/plasma triglyceride and plasma apoE levels. APOE*2 (Lys146-->Gln) and APOE*3-Leiden allele carriers were found to differ significantly in: (a) plasma apoE levels, (b) in the amounts of triglycerides in the VLDL and VLDL + IDL fraction, and (c) in the amount of cholesterol in the VLDL and VLDL + IDL fraction relative to the amount of triglyceride in these fractions. In the APOE*2 (Lys146-->Gln) allele carriers the VLDL and VLDL + IDL fraction is relatively rich in triglycerides as compared with that in APOE*3-Leiden carriers. We hypothesize that these two rare mutations of apoE both lead to dominantly inherited forms of FD along different underlying metabolic defects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083367      PMCID: PMC295210          DOI: 10.1172/JCI117443

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins.

Authors:  G Utermann; M Jaeschke; J Menzel
Journal:  FEBS Lett       Date:  1975-08-15       Impact factor: 4.124

2.  Human apolipoprotein E. The complete amino acid sequence.

Authors:  S C Rall; K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

3.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

Authors:  K H Weisgraber; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

4.  Functionally inactive apolipoprotein E3 in a type III hyperlipoproteinaemic patient.

Authors:  L M Havekes; J A Gevers Leuven; E van Corven; E de Wit; J J Emeis
Journal:  Eur J Clin Invest       Date:  1984-02       Impact factor: 4.686

5.  Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.

Authors:  S C Rall; K H Weisgraber; T L Innerarity; R W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

6.  Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3.

Authors:  R J Havel; L Kotite; J P Kane; P Tun; T Bersot
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

7.  The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.

Authors:  T L Innerarity; E J Friedlander; S C Rall; K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

8.  Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.

Authors:  S C Rall; K H Weisgraber; T L Innerarity; T P Bersot; R W Mahley; C B Blum
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

9.  The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.

Authors:  K H Weisgraber; T L Innerarity; K J Harder; R W Mahley; R W Milne; Y L Marcel; J T Sparrow
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

10.  Human apolipoprotein E isoprotein subclasses are genetically determined.

Authors:  V I Zannis; P W Just; J L Breslow
Journal:  Am J Hum Genet       Date:  1981-01       Impact factor: 11.025

View more
  5 in total

Review 1.  Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models.

Authors:  K W van Dijk; M H Hofker; L M Havekes
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

2.  Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.

Authors:  M van Dam; M Zwart; F de Beer; A H M Smelt; M H Prins; M D Trip; L M Havekes; P J Lansberg; J J P Kastelein
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

3.  Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.

Authors:  B J van Vlijmen; H B van 't Hof; M J Mol; H van der Boom; A van der Zee; R R Frants; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

Review 4.  Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Authors:  Britt E Heidemann; Charlotte Koopal; Alexis Baass; Joep C Defesche; Linda Zuurbier; Monique T Mulder; Jeanine E Roeters van Lennep; Niels P Riksen; Christopher Boot; A David Marais; Frank L J Visseren
Journal:  Clin Genet       Date:  2022-08-22       Impact factor: 4.296

Review 5.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.